← Oncology Approval Tracker

FDA DECISION ·

Retevmo

selpercatinib · Eli Lilly

Accelerated approvalNew or expanded indicationThyroid cancer and RET fusion-positive solid tumors
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Children aged 2 years and older with FDA test-confirmed RET-altered tumors: advanced or metastatic RET-mutant medullary thyroid cancer needing systemic therapy; advanced or metastatic RET fusion-positive thyroid cancer needing systemic therapy and refractory to radioactive iodine when appropriate; or locally advanced or metastatic RET fusion-positive solid tumors after systemic treatment progression or without satisfactory alternatives.

LAMPGEN ANALYSIS

Why it matters

The pediatric extension brought RET-targeted treatment to younger children across several rare populations.

What research teams should watch

Use the disease-specific RET test and eligibility criteria, and coordinate age-appropriate drug administration and pediatric follow-up.

PRIMARY RECORDS

Sources